Evidence map›Paper›PMID 29658093›Full record

ArticleAnalytical and bioanalytical chemistry2018

Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA.

Joanna Nizioł, Vincent Bonifay, Krzysztof Ossoliński, Tadeusz Ossoliński, Anna Ossolińska, Jan Sunner, Iwona Beech, Adrian Arendowski, Tomasz Ruman

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Joanna NiziołFaculty of Chemistry, Rzeszow University of Technology, 35-959, Rzeszow, Poland. jniziol@prz.edu.pl.
Vincent BonifayDepartment of Microbiology and Plant Biology, University of Oklahoma, Norman, OK, 73019, USA.
Krzysztof OssolińskiDepartment of General Surgery and Urology, John Paul II Hospital, Grunwaldzka 4 St., 36-100, Kolbuszowa, Poland.
Tadeusz OssolińskiDepartment of General Surgery and Urology, John Paul II Hospital, Grunwaldzka 4 St., 36-100, Kolbuszowa, Poland.
Anna OssolińskaDepartment of General Surgery and Urology, John Paul II Hospital, Grunwaldzka 4 St., 36-100, Kolbuszowa, Poland.
Jan SunnerDepartment of Chemistry, Montana State University, 103 Chemistry and Biochemistry Building, Bozeman, MT, 59717, USA.
Iwona BeechCenter of Biofilm Engineering, Montana State University, 366 Barnard Hall, Bozeman, MT, 59717, USA.
Adrian ArendowskiFaculty of Chemistry, Rzeszow University of Technology, 35-959, Rzeszow, Poland.
Tomasz RumanFaculty of Chemistry, Rzeszow University of Technology, 35-959, Rzeszow, Poland.
John Paul II Hospital · PLRzeszów University of Technology · PLMontana State University · USUniversity of Oklahoma · US

Funding

Narodowe Centrum Nauki 2016/23/B/ST4/00062
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is the most prevalent and lethal malignancy of the kidney. Despite all the efforts made, no tissue biomarker is currently used in the clinical management of patients with kidney cancer. A search for possible biomarkers in urine for clear cell renal cell carcinoma (ccRCC) has been conducted. Non-targeted metabolomic analyses were performed on paired samples of surgically removed renal cancer and normal tissue, as well as on urine samples. Extracts were analyzed by liquid chromatography/high-resolution mass spectrometry (LC-HRMS). Hydroxybutyrylcarnitine, decanoylcarnitine, propanoylcarnitine, carnitine, dodecanoylcarnitine, and norepinephrine sulfate were found in much higher concentrations in both cancer tissues (compared with the paired normal tissue) and in urine of cancer patients (compared with control urine). In contrast, riboflavin and acetylaspartylglutamate (NAAG) were present at significantly higher concentrations both in normal kidney tissue as well as in urine samples of healthy persons. This preliminary study resulted in the identification of several compounds that may be considered potential clear cell renal carcinoma biomarkers. Graphical abstract PLS-DA plot based on LC-MS data for normal and cancer human tissue samples. The aim of this work was the identification of up- and downregulated compounds that could potentially serve as renal cancer biomarkers.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCarcinoma, Renal CellChromatography, LiquidHumansKidneyKidney NeoplasmsMetabolomicsMiddle AgedTandem Mass SpectrometryBiomarkers, TumorBiomarkerCancer biomarkerKidneyMass spectrometryRenal cell carcinoma

Identifiers

PMID29658093
PMCPMC5956006
OpenAlexW2799539744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.